Testosterone Antagonizes Doxorubicin-Induced Senescence of Cardiomyocytes

Paola Altieri, PhD; Chiara Barisione, PhD; Edoardo Lazzarini, PhD; Anna Garuti, PhD; Gian Paolo Bezante, MD; Marco Canepa, MD, PhD; Paolo Spallarossa, MD; Carlo Gabriele Tocchetti, MD, PhD; Sveva Bollini, PhD; Claudio Brunelli, MD; Pietro Ameri, MD, PhD

Background—Chronic cardiotoxicity is less common in male than in female patients receiving doxorubicin and other anthracyclines at puberty and adolescence. We hypothesized that this sex difference might be secondary to distinct activities of sex hormones on cardiomyocyte senescence, which is thought to be central to the development of long-term anthracycline cardiomyopathy.

Methods and Results—H9c2 cells and neonatal mouse cardiomyocytes were exposed to doxorubicin with or without prior incubation with testosterone or 17β-estradiol, the main androgen and estrogen, respectively. Testosterone, but not 17β-estradiol, counteracted doxorubicin-elicted senescence. Downregulation of telomere binding factor 2, which has been pinpointed previously as being pivotal to doxorubicin-induced senescence, was also prevented by testosterone, as were p53 phosphorylation and accumulation. Pretreatment with the androgen receptor antagonist flutamide, the phosphatidylinositol 3 kinase inhibitor LY294002, and the nitric oxide synthase inhibitor L-NG-nitroarginine methyl ester abrogated the reduction in senescence and the normalization of telomere binding factor 2 levels attained by testosterone. Consistently, testosterone enhanced the phosphorylation of AKT and nitric oxide synthase 3. In H9c2 cells, doxorubicin-stimulated senescence was still observed up to 21 days after treatment and increased further when cells were rechallenged with doxorubicin 14 days after the first exposure to mimic the schedule of anthracycline-containing chemotherapy. Remarkably, these effects were also inhibited by testosterone.

Conclusions—Testosterone protects cardiomyocytes against senescence caused by doxorubicin at least in part by modulating telomere binding factor 2 via a pathway involving the androgen receptor, phosphatidylinositol 3 kinase, AKT, and nitric oxide synthase 3. This is a potential mechanism by which pubescent and adolescent boys are less prone to chronic anthracycline cardiotoxicity than girls. (J Am Heart Assoc. 2016;5:e002383 doi: 10.1161/JAHA.115.002383)

Key Words: cardiotoxicity • doxorubicin • senescence • sex • testosterone

Anthracyclines are chemotherapeutic drugs used to treat several solid and hematological malignancies. A major dose-limiting side effect of these compounds is cardiac toxicity, which most often presents as subclinical myocardial dysfunction or overt heart failure toward the end of chemotherapy or later on, even after many years.¹ This delayed form of anthracycline cardiotoxicity is referred to as chronic and has complex pathogenesis.²,³ It has been shown recently that anthracyclines cause senescence of cardiomyocytes.⁴ This event is central to the development of late-onset anthracycline cardiomyopathy in mice⁵ and may be so in humans.⁶

Female patients treated with anthracycline at puberty or adolescence are more susceptible to chronic anthracycline cardiotoxicity than male patients.⁷,⁸ Anthracyclines do not accumulate in the adipose tissue; therefore, it has been postulated that their clearance is lower—and the concentrations reached in nonadipose organs, such as the heart, are higher—in female patients than in male patients with the same body surface area because the former have more fat mass than the latter.⁸ Nevertheless, differences in the sex hormone milieu might also account for the predisposition of pubescent and adolescent girls to cardiac toxicity of anthracyclines. In fact, left ventricular function and survival following administration of doxorubicin, the prototype of anthracyclines, are significantly worse in mice knockout for the androgen...
receptor (AR) than in controls, pointing to a protective role of androgen against anthracycline cardiac damage.9

In this study, we compared the effect of testosterone and 17β-estradiol, the main androgen and estrogen, respectively, on an established cell model of doxorubicin-induced senescence of cardiomyocytes.10 After finding that testosterone, but not 17β-estradiol, inhibited senescence elicited by doxorubicin, we sought to characterize the relevant signaling pathway.

Methods

Unless otherwise indicated, all materials were supplied by Sigma-Aldrich.

Animals

C57BL/6 breeders were purchased from Charles River Research Models and Services (Lecco, Italy) and housed in the animal facility of the IRCCS AOU San Martino—IST National Institute for Cancer Research in Genova, Italy. Primary mouse neonatal cardiomyocytes were isolated from the hearts of pups aged 2 days. Procedures complied with Italian national law concerning the use of animals for scientific purposes and were approved by the institutional animal care and use committee.

Cell Culture and Experimental Design

Experiments were carried out with H9c2 cells, and then results were confirmed with neonatal cardiomyocytes.

The rat embryonic cardiac cell line H9c2 was purchased from the American Type Culture Collection (CRL-1446; Rockville, MD), cultured as reported previously,11 and treated at a density of 70% to 80%. These cells express the male-specific gene sex-determining region Y (SRY) and have the testosterone metabolizing enzymes 5α-reductase and aromatase.12

Primary cardiomyocytes were obtained as described previously, with minor modifications.13 Briefly, hearts were harvested, digested overnight in a 0.06% (wt/vol) solution of trypsin (Gibco, Life Technologies), and further subjected to multiple digestions with a 0.1% type II collagenase solution (Worthington Biochemicals). Cells were preplated for 2 periods of 60 minutes each to enrich for cardiomyocytes and subsequently cultured in DMEM containing 4.5 g/L glucose supplemented with 10% FBS, 2 mmol/L l-glutamine, and 100 U/mL penicillin. Purity of the culture was routinely checked by immunofluorescence with a monoclonal antianimal treatment.

The complete culture medium was replaced with one with 0.5% FBS. Cells were exposed to 0.1 μmol/L doxorubicin (Adriblastina; Pfizer) for 3 hours10 with or without prior incubation with testosterone or 17β-estradiol for 15 minutes. Both hormones were preliminarily tested at different concentrations ranging from 0.1 to 1000 nmol/L (Figure 1). Testosterone was subsequently used at 10 nmol/L because this dose maximally reduced doxorubicin-induced senescence (Figure 1). Importantly, 10 nmol/L is within the normal values of circulating testosterone found in boys at puberty and adolescence.14 In girls at the same age, physiological concentrations of 17β-estradiol are around 1 nmol/L.14 Markers of senescence and telomere binding factor 2 (TRF2) levels were evaluated 45 hours after removing doxorubicin, whereas p53 was studied after 21 hours. The possibility of prolonged culturing of the H9c2 cell line was exploited to assess senescence over the long term. Cells were challenged with 0.1 μmol/L doxorubicin as in short-term experiments but then were maintained in complete medium for 7, 14, or 21 days before determining senescence. Furthermore, the effect on senescence of a second 3-hour pulse of 0.1 μmol/L doxorubicin, given 14 days after the first, was evaluated, as was the effect of preincubation with testosterone.

To identify the intracellular mediators of testosterone activity, cells were pretreated for 1 hour with the AR antagonist flutamide (10 μmol/L), the phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002 (20 μmol/L; Calbiochem, Merck), the p38 MAPK inhibitor SB203580 (10 μmol/L), and the JNK inhibitor SP600125 (20 μmol/L); for 45 minutes with the nitric oxide synthase (NOS) inhibitor L-NG-nitroarginine methyl ester, L-NAME (1 mmol/L), or with relevant vehicles.

To analyze AKT and NOS-3 phosphorylation, cells were preincubated with testosterone or left untreated for 15 minutes followed by 20-minute exposure to doxorubicin or no treatment.

Assessment of Senescence

Three different features of senescence were investigated, namely, enhanced β-galactosidase activity related to increased lysosomal content, formation of heterochromatin foci, and expression of the cell cycle inhibitor p16INK4a.15 Staining for senescence-associated (SA) β-galactosidase was performed as described by Dimri et al,16 and positive cells were counted out of total cells in 100 randomly chosen low-power fields (×100). After staining for SA β-galactosidase, 0.13 mg/mL DAPI was added for 2 minutes at room temperature to costain for SA heterochromatin foci.17 Immunocytochemistry for p16INK4a was carried out as described below. For each sample, images including a total of 300 cells were taken randomly and digitized at 256 levels of gray. The optical density of signals was measured with the Leica Q500 MC Image Analysis System.
Western Blotting

Cells were lysed in lysis buffer (20 mmol/L Tris HCl [pH 7.5], 150 mmol/L NaCl, 1 mmol/L Na₂-EDTA, 1 mmol/L EGTA, 1% NP40, 2.5 mmol/L Na₂P₂O₇, and 1 mmol/L β-glycerophosphate). One mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L Na₃VO₄, 1 mmol/L NaF, and a protease inhibitor cocktail (Thermo Fisher Scientific) were added to the buffer immediately before lysing.

The following primary antibodies were used (clones are indicated for monoclonal antibodies): anti–phosphorylated AKT (Ser⁴⁷³, clone D9E; Cell Signaling Technology), anti–phosphorylated AKT (Thr³⁰⁸), anti-AKT (H-136), anti–phosphorylated NOS-3 (Ser¹¹⁷⁷, 15E2; Santa Cruz Biotechnology), anti–NOS-3 (6H2; Cell Signaling Technology), anti-TRF2 (4S794.15; Imgenex, Novus Biologicals), anti–phosphorylated p53 (Ser¹⁵, D4S1H; Cell Signaling Technology), anti-p53, anti-GAPDH (FL-335), anti-AR (Millipore), and anti-ERK1/2. After
incubation with proper horseradish peroxidase–conjugated secondary antibody (Santa Cruz Biotechnology), bands were visualized with Clarity Western ECL Substrate (Bio-Rad) and quantified by densitometry using an image analysis system (UVitec). The quantity of phosphorylated AKT, NOS-3, and p53 was normalized for the amount of total protein. Levels of GAPDH and ERK1/2, respectively, were used to normalize the expression of TRF2 and p53 at 24 and 48 hours and the expression of AR at 7, 14, and 21 days.

Immunocytochemistry

Cells were grown and treated on slides. At the end of experiments, they were fixed, permeabilized, and immunostained for p16\(^{INK4a}\) with a specific rabbit primary antibody (Proteintech). Biotinylated secondary antibody (Vector), horse-radish peroxidase–streptavidin (Vector), and 3,3’-diaminobenzidine (DAB Peroxidase Substrate Kit; Vector) were used to detect the bound primary antibody.\(^{18}\)

Statistical Analysis

Results are presented as mean±SEM of at least 3 independent replicates. Because of the small sample sizes, comparisons were drawn by Kruskal–Wallis followed by Dunn’s multiple comparisons test. Statistical significance was set at \(P<0.05\).

Results

Testosterone Protects H9c2 Cells Against Doxorubicin-Induced Senescence

The 3-hour treatment of H9c2 cells with doxorubicin significantly increased the percentage of senescent cells, as assessed by staining for SA β-galactosidase (Figure 2A and 2C), p16\(^{INK4a}\) (Figure 2B and 2C), and SA heterochromatin foci (Figure 2D). Testosterone antagonized senescence elicited by doxorubicin (Figure 2A through 2C). In contrast, 17β-estradiol was not protective at either 100 nmol/L (Figure 2A through 4F). The effect of testosterone on TRF2 was abolished by pretreatment with flutamide and LY294002 (Figure 4D through 4F), indicating that it was dependent on AR and PI3K.

NOS-3 Is Implicated in Testosterone Prevention of Doxorubicin-Triggered Senescence and TRF2 Downregulation

Consistent with previous studies,\(^{20}\) the activatory phosphorylation of NOS-3 at Ser\(^{1177}\) increased in response to testosterone in H9c2 cells in a PI3K-dependent manner (Figure 5A). Because NOS-3\(^{−/−}\) mice have lower levels of TRF2 than wild types,\(^{25}\) we considered the possibility that NOS-3 was implicated in the signaling pathway linking testosterone to the modulation of TRF2 and senescence. Indeed, pretreatment of cells with the NOS inhibitor l-NAME reduced the ability of testosterone to prevent doxorubicin-induced TRF2 downregulation (Figure 5B) and senescence (Figure 5C).

Confirmation of Results in Primary Neonatal Cardiomyocytes

Testosterone substantially reduced doxorubicin-caused senescence of primary mouse neonatal cardiomyocytes, whereas 17β-estradiol was only marginally effective (Figure 6A and 6C). Protection of testosterone was lost when cells were preincubated with flutamide, LY294002, or l-NAME but not with a p38 or JNK inhibitor (Figure 6B and 6C). Moreover, testosterone almost normalized the expression of
TRF2, and this effect was opposed by flutamide and LY294002 (Figure 6D).

Testosterone Inhibition of Doxorubicin-Initiated Senescence is Long-Lasting

In agreement with our earlier findings, the prosenescent response of H9c2 cardiomyoblasts to 3-hour treatment with doxorubicin persisted over time. After being challenged with doxorubicin, cells proliferated more slowly and were passage, on average, once a week compared with 2 or 3 times per week for control. In addition, a higher number of treated than control cells were positive for SA β-galactosidase after 7, 14, and 21 days (Figure 7A). Conversely, cells preincubated with testosterone and then exposed to doxorubicin were split twice a week and exhibited less SA β-galactosidase positivity than those treated with doxorubicin only, with this effect being AR dependent (Figure 7A).
Figure 3. The androgen receptor/phosphatidylinositol 3 kinase/AKT pathway mediates T inhibition of Dox-induced senescence of H9c2 cardiomyoblasts. A, Percentage of SA β-galactosidase-positive H9c2 cells counted after no treatment or exposure to Dox with or without prior incubation with T, F and then T (F+T), LY and then T (LY+T), SB and then T (SB+T), or SP and then T (SP+T). B, Signal intensity quantification of the immunostaining for p16\(^{INK4a}\) after the same treatments as in (A). C and D, Representative pictures of H9c2 cells stained for SA β-gal (C) and p16\(^{INK4a}\) (D). Magnification is ×200 in (C) and ×400 in (D); bars correspond to 50 μm in both panels. Data in graphs are means±SEM (7 and 4 observations for each SA β-gal and p16\(^{INK4a}\) group, respectively); *P<0.05, **P<0.01, and ***P<0.005 vs no treatment. AU indicates arbitrary units; Ctr, control; Dox, doxorubicin; F, flutamide; LY, LY294002 (phosphatidylinositol 3 kinase inhibitor); SA β-gal, senescence-associated β-galactosidase; SB, SB203580 (p38 inhibitor); SP, SP600125 (JNK inhibitor); T, testosterone.
To further gain insight into the prolonged protection against doxorubicin cardiotoxicity conferred by testosterone, H9c2 cells were incubated with doxorubicin once or twice in 2 weeks, with or without being pretreated with testosterone. These experiments also allowed us to obtain data that were more easily translatable to the clinical setting, in which

Figure 4. T stimulates AKT phosphorylation and prevents the changes in TRF2 and p53 levels caused by doxorubicin. A through C, Representative western blots (A) and band densitometry (B and C) for phosphorylated AKT in H9c2 cells preincubated with T or left untreated for 15 minutes followed by 20-minute exposure to Dox or no treatment. D through F, Representative western blots (D) and band densitometry (E through G) of TRF2 and p53 protein expression in H9c2 cells after no treatment or exposure to Dox with or without prior incubation with T, F, and then T (F+T), or LY and then T (LY+T). Data are shown as means±SEM (3 observations per condition); P values are from Kruskal–Wallis test. Dunn’s multiple comparisons test: **P<0.01 vs no treatment. Ctr indicates control; Dox, doxorubicin; F, flutamide; LY, LY294002 (phosphatidylinositol 3 kinase inhibitor); p, phosphorylated; T, testosterone; TRF2, telomere binding factor 2.
Figure 5. NOS-3 is implicated in testosterone prevention of Dox-triggered downregulation of TRF2 and senescence. A, Band densitometry and representative western blot for phosphorylated NOS-3 in H9c2 cells pretreated or not with LY and then incubated with T for 15 or 15+20 minutes, as indicated. B, Representative western blot and band densitometry of TRF2 protein expression in H9c2 cells after no treatment or exposure to Dox with or without prior incubation with T or LN and then T (LN+T). C, Percentage of SA β-galactosidase–positive H9c2 cells counted after the same treatments as in (B). Data are means±SEM. Western blot experiments included 3 replicates for each condition, whereas SA β-galactosidase was assessed 4 times for no treatment and Dox and 7 times for T or LN+T followed by Dox. Kruskal–Wallis P values are displayed above the graphs. Dunn’s multiple comparisons test: ****P<0.0001 vs no treatment. Ctr indicates control; Dox, doxorubicin; LN, L-NG-nitroarginine methyl ester, or L-NAME; LY, LY294002 (phosphatidylinositol 3 kinase inhibitor); NOS, nitric oxide synthase; p, phosphorylated; SA β-gal, senescence-associated β-galactosidase; T, testosterone; TRF2, telomere binding factor 2.
Figure 6. T inhibits Dox-caused senescence of primary neonatal cardiomyocytes via androgen receptor/phosphatidylinositol 3 kinase/nitric oxide synthase 3. A and B, Percentage of SA β-gal-positive primary mouse neonatal cardiomyocytes after no treatment or exposure to Dox with or without prior incubation with T or E2 (A) or T, F and then T (F+T), LY and then T (LY+T), LN and then T (LN+T), SB and then T (SB+T), or SP and then T (SP+T) (B). C, Representative pictures of the staining for SA β-gal after the same treatments as in (A) and (B). Magnification is ×200, and bars correspond to 50 μm. D, Representative western blot and band densitometry of TRF2 protein expression in primary mouse neonatal cardiomyocytes after no treatment or exposure to Dox with or without prior incubation with T, F and then T (F+T), or LY and then T (LY+T). Means±SEM and Kruskal–Wallis P values are shown in graphs (western blots: 3 observations per group; SA β-gal: 7 assessments for no treatment, Dox, and T or E2 followed by Dox; 4 for all the other conditions). Dunn’s multiple comparisons test: *P<0.05, **P<0.01, ***P<0.005, and ****P<0.001 vs no treatment; #P<0.05 vs Dox. Ctr indicates control; Dox, doxorubicin; E2, 17β-estradiol; F, flutamide; LN, L-NG-nitroarginine methyl ester, or L-NAME (nitric oxide synthase inhibitor); LY, LY294002 (phosphatidylinositol 3 kinase inhibitor); SA β-gal, senescence-associated β-galactosidase; SB, SB203580 (p38 inhibitor); SP, SP600125 (JNK inhibitor); T, testosterone; TRF2, telomere binding factor 2.
patients receive cycles of anthracycline-containing chemotherapy regimens every 2 or 3 weeks. Two pulses of doxorubicin 14 days apart caused senescence of H9c2 cardiomyoblasts in an additive manner (Figure 7B). Pretreatment with testosterone before each incubation with doxorubicin decreased the percentage of SA β-galactosidase–positive cells. Furthermore, senescence was reduced, albeit to a slightly lesser extent, when only the second pulse of doxorubicin was preceded by testosterone (Figure 7B). These results prompted us to investigate the expression of AR, which had proved to be necessary for testosterone action, over the 21 days of culturing. Surprisingly, and unlike observations at 24 and 48 hours (Figure 4D through 4F), GAPDH protein expression was substantially reduced by doxorubicin at 7, 14, and 21 days (Figure 8). Consequently, the expression of AR was normalized against that of ERK1/2, which did not vary throughout the experiment. At every time point, levels of AR were significantly lower in doxorubicin-treated cells than in control cells and were partially restored by preincubation with testosterone via AR (Figure 8).

Discussion

Senescence of cardiac cells is considered to be of primary importance for the occurrence of anthracycline-related cardiomyopathy. Doxorubicin induces a senescent-like phenotype in cardiomyocytes, with an abnormal pattern of troponin phosphorylation that may lead to inefficient cardiac contraction. Moreover, doxorubicin causes senescence of resident cardiac progenitor cells (CPCs), which preserve myocardial tissue homeostasis following stress. It has been proposed that senescence of CPCs in response to doxorubicin may be especially relevant at a young age because CPCs may no longer be able to activate a repair program for minor cardiac injuries, which therefore build up until they irreversibly affect cardiac structure and function. In fact, mice injected with doxorubicin shortly after birth have normal hearts as adults but exhibit pathological eccentric hypertrophy following endurance training and more extensive myocardial infarction than wild-type littermates after coronary artery ligation, along with fewer, less proliferating, and less differentiating CPCs.

In the present work, we found that testosterone antagonized doxorubicin-initiated senescence of both H9c2 cells and primary neonatal cardiomyocytes, whereas the effectiveness of 17β-estradiol was poor. This new information integrates the previous demonstration that AR deletion enhances cardiomyocyte apoptosis, cardiac remodeling, and mortality caused by doxorubicin in mice. Moreover, it substantiates the hypothesis that differences in sex hormones may explain, at least in part, the higher risk of left ventricular dysfunction and heart failure that has been demonstrated in female survivors of cancer in puberty and adolescence who were treated with anthracyclines. It is possible that pharmacokinetic factors also contribute to the young female predisposition to anthracycline cardiotoxicity. The uptake of anthracyclines by adipose tissue is lower than by other organs. Consequently, the higher the fat mass, the higher the concentration of anthracyclines in the bloodstream and in nonadipose tissues, including the heart. Anthracyclines are dosed based on body surface area, but from puberty and thereafter, female patients generally have higher percentages of body fat than male patients, thus they might be more susceptible to cardiac side effects of anthracyclines.

No clear sex difference in the incidence of anthracycline-related cardiotoxicity has been found in the adult oncological population. This may be due to the fact that anthracycline-based chemotherapies are most often given for breast cancer, which almost exclusive for the female sex. Nevertheless, the paradigm that androgen confers an advantage against cardiotoxicity of doxorubicin may be not valid in adulthood because estrogen during fertile age favorably influences cardiovascular risk factors and has direct beneficial activity on the heart.
Telomere dysfunction is a well-established cause of senescence. In a landmark paper, Maejima and colleagues showed that primary neonatal cardiomyocytes display markers of senescence and reduced telomerase activity on incubation with doxorubicin. Expanding their observations, we previously demonstrated that TRF2 levels are decreased by treatment with doxorubicin and that silencing of Terf2 is sufficient to trigger senescence in H9c2 cells and neonatal cardiomyocytes. Subsequent studies have revealed that doxorubicin also induces senescence of vascular smooth muscle cells by downregulating TRF2. In this study, it was shown that inhibition of doxorubicin-elicted senescence by testosterone is paralleled by the normalization of TRF2 expression, suggesting that prevention of TRF2 imbalance and telomeric dysfunction is at least one of the mechanisms by which testosterone counteracts cardiomyocyte senescence secondary to doxorubicin exposure.

Testosterone acts via AR, a steroid hormone receptor that classically works as a ligand-activated transcription factor, but it can also localize to the plasma membrane and initiate nongenomic signaling cascades. In cardiomyocytes, this modality of action has already been reported, for example, for the modulation of intracellular calcium concentrations and action potential duration or for the stimulation of hypertrophy. This study provides evidence that antagonism of doxorubicin-induced senescence and TRF2 downregulation is another nongenomic effect of testosterone and that it occurs through a signaling pathway involving PI3K, AKT, and NOS-3.

Activation of AKT has repeatedly been linked to inhibition of senescence in cardiovascular cells. Interestingly, phosphorylation of AKT at Ser473 is decreased in senescent CPCs. Interestingly, phosphorylation of AKT at this site has specifically been related to cardioprotection against doxorubicin, which is enhanced when PH domain leucine-rich-repeat protein phosphatase 1, which selectively dephosphorylates AKT at Ser473, is knocked down. Furthermore, AKT activation has been associated with TRF2 induction and PI3K or AKT inhibition with diminished TRF2 levels in endothelial cells.

Based on the fact that NOS-3 is a downstream target of the AR/PI3K/AKT signal transduction cascade in cardiomyocytes and on the finding that protection by testosterone was attenuated by pretreatment with L-NAME, we propose that NOS-3 mediates androgen modulation of TRF2 and antagonism of doxorubicin-stimulated senescence. In addition to the AR/PI3K/AKT/NOS-3 cascade, however, other nongenomic cascades may underlie testosterone regulation of TRF2 and senescence. Nitric oxide release by NOS-3, for example, has recently been demonstrated to reduce H2O2-induced senescence of H9c2 cells by improving redox state.

In apparent discordance with our results, mice knockout for NOS3 are less sensitive to doxorubicin-triggered cardiac cell apoptosis, intramyocardial production of reactive oxygen species, left ventricular dysfunction, and death. Furthermore, cardiomyocyte-specific overexpression of NOS3 exacerbates cardiac toxicity of doxorubicin. This phenotype has been ascribed to the involvement of NOS-3 in the so-called redox cycling of anthracyclines, namely, the reduction to semiquinone radicals that then react with oxygen and undergo oxidation with generation of superoxide anion. In contrast, another NOS isozyme, NOS-1, is overexpressed in NOS-3 knockouts, and it has been suggested that NOS-1 might actually be responsible for the resistance to doxorubicin cardiac damage associated with NOS3 deletion. Consequently, NOS activity may be generally protective against doxorubicin cardiotoxicity although with differences in the involved isoform, depending on the experimental model.

We observed the most intense decrease in doxorubicin-initiated senescence of cardiomyocytes with 10 nmol/L testosterone.
Testosterone, which is well within the range of normal plasma values for pubescent and adolescent boys. Inhibition of senescence was not as strong with 100 nmol/L, a supra-physiological concentration of testosterone, and was lost with 1000 nmol/L testosterone, which is a very high dose. This latter dose may no longer be able to activate antisenes-cence pathways, similar to what has been reported previously for the modulation of calcium transients by testosterone, or it may stimulate signaling cascades that oppose those preventing doxorubicin-induced senescence. In any case, it should be noted that important variations in doxorubicin and testosterone metabolism and action likely exist between cell cultures and the whole human body.

In our experiments, doxorubicin after testosterone differently influenced the phosphorylation status of Ser and Thr of AKT. There are several possible reasons for this phenomenon, including doxorubicin modulation of the activity of AKT kinases and phosphatases and of the interaction between AKT and its binding proteins. Nevertheless, it should be kept in mind that the effect of doxorubicin on AKT phosphorylation appears to be importantly affected by the experimental setting, up to the point that opposite results have been obtained with the same animal model.

Doxorubicin persistently downregulated AR protein in H9c2 cardiomyoblasts, and pretreatment with testosterone partially rescued its expression, possibly allowing androgen contained in the culture medium to antagonize senescence triggered by doxorubicin. Strikingly, a reduction in GAPDH protein expression was also observed during prolonged culturing. It is known that doxorubicin causes profound posttranslational modi-  

In our experiments, doxorubicin after testosterone differently influenced the phosphorylation status of Ser and Thr of AKT. There are several possible reasons for this phenomenon, including doxorubicin modulation of the activity of AKT kinases and phosphatases and of the interaction between AKT and its binding proteins. Nevertheless, it should be kept in mind that the effect of doxorubicin on AKT phosphorylation appears to be importantly affected by the experimental setting, up to the point that opposite results have been obtained with the same animal model.

Doxorubicin persistently downregulated AR protein in H9c2 cardiomyoblasts, and pretreatment with testosterone partially rescued its expression, possibly allowing androgen contained in the culture medium to antagonize senescence triggered by doxorubicin. Strikingly, a reduction in GAPDH protein expression was also observed during prolonged culturing. It is known that doxorubicin causes profound posttranslational modi-

In conclusion, this work offers a biological explanation for the relative resistance of the male heart to anthracycline toxicity. In general, it adds to the knowledge of the cardiovascular effects of testosterone and may form the basis for additional research into the role of this hormone in stress-induced senescence of cardiac cells.

Acknowledgments

The authors acknowledge Dr Barbara Rebisco, Director of the Antiblastic Drug Unit, IRCCS AOUI San Martino—IST National Institute for Cancer Research, Genova, Italy, for providing doxorubicin.

Sources of Funding

This work was partially supported by a grant funded by the University of Genova to Pietro Ameri (Progetto di Ricerca d’Ateneo 2014).

Disclosures

None.

References


DOI: 10.1161/JAHA.115.002383
Testosterone Inhibits Doxorubicin Senescence

Altieri et al


Testosterone Antagonizes Doxorubicin–Induced Senescence of Cardiomyocytes
Paola Altieri, Chiara Barisione, Edoardo Lazzarini, Anna Garuti, Gian Paolo Bezante, Marco Canepa, Paolo Spallarossa, Carlo Gabriele Tocchetti, Sveva Bollini, Claudio Brunelli and Pietro Ameri

*J Am Heart Assoc.* 2016;5:e002383; originally published January 8, 2016;
doi: 10.1161/JAHA.115.002383

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/5/1/e002383